Program
BNT3210
A development code.
Its studies are led by BioNTech.
Furthest: phase 2, since Oct 15, 20261 company-led study, 1 open or runningNext primary completion: Oct 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTech | 11 open or running | phase 2since Oct 15, 2026 | Oct 15, 2026 | Oct 2029phase 2 · NCT07886684 |
Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 15, 2026First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07886684 · 173 planned
Ahead
- Oct 2029Primary completion: phase 2 study in Advanced Solid TumorsNCT07886684
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07886684Advanced Solid Tumors | 2 | Not yet recruiting | Oct 2029 | 173 |
How it is read
Names in the registry
- “BNT3210”, 1 entry
Codes read as this program: BNT3210.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.